Lucentis Disease Interactions
There are 2 disease interactions with Lucentis (ranibizumab ophthalmic).
Intravitreal injections (applies to Lucentis) ocular infections
Major Potential Hazard, High plausibility. Applicable conditions: Uveitis, Orbital Infection, Infectious Endophthalmitis, Infectious Optic Neuritis
Drugs requiring intravitreal administration (including aflibercept, faricimab, pegaptanib, and ranibizumab) are contraindicated in patients with active intraocular inflammation or ocular/periocular infections; intravitreal injections have been associated with endophthalmitis. Patients should be advised to seek immediate medical attention from an ophthalmologist if the eye becomes red, photosensitive, or painful, or if a change in vision occurs in the days following drug administration.
Ranibizumab intravitreal injection (applies to Lucentis) increased intraocular pressure
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Glaucoma/Intraocular Hypertension
Increases in intraocular pressure have been reported both pre- injection and post- injection (at 60 minutes) while being treated with ranibizumab. Intraocular pressure should be monitored prior and following intravitreal injection with ranibizumab and managed appropriately.
Switch to professional interaction data
Lucentis drug interactions
There are 2 drug interactions with Lucentis (ranibizumab ophthalmic).
More about Lucentis (ranibizumab ophthalmic)
- Lucentis consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (15)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anti-angiogenic ophthalmic agents
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Vabysmo
Vabysmo eye injection is used to treat eye diseases neovascular (wet) age-related macular ...
Eylea
Eylea is used to treat neovascular (wet) age-related macular degeneration (AMD), macular edema ...
Izervay
Izervay (avacincaptad pegol) is used for treating geographic atrophy (GA) due to age-related ...
Syfovre
Syfovre (pegcetacoplan) treatment for geographic atrophy (GA) a form of dry age-related macular ...
Eylea HD
Eylea HD is used to treat neovascular (wet) age-related macular degeneration (AMD), diabetic ...
Pavblu
Pavblu (aflibercept-ayyh) is a biosimilar to Eylea that may be used to treat the following eye ...
Yesafili
Yesafili (aflibercept-jbvf) is an interchangeable biosimilar to Eylea that may be given by ...
Faricimab ophthalmic
Faricimab ophthalmic is used for diabetic macular edema, macular degeneration, macular edema ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.